Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Cancer Resources / Genetics
Last Modified: May 14, 2009
![]()
Dear OncoLink "Ask The Experts,"
FAP (familial adenomatous polyposis) is very prevalent in our family. I lost my husband at 33 y.o. and his brother at 38 y.o. to colon cancer, at which time it was discovered that FAP was the culprit. Two of my sons were diagnosed, one died of the disease, and one is alive and well today. I also lost one grandson at the age of 18 to the disease. I have a 37-year-old daughter who has not presented with any polyps or other symptoms of FAP. Do you feel [that] it is safe to say that she does not have the mutation? My son has had 3 genetic tests done in an effort to locate his mutation so that my daughter and her 2-year-old son could get blood tests to see if they have it, but they have not been able to locate the mutation in any of the affected family members.
![]()
Jill Stopfer, MS, CGC, Certified Genetic Counselor, responds:
Your daughter is at a 50% risk of having the gene that leads to FAP, since one parent had the gene and one does not. A woman who is at 50% risk for FAP, but who has had consistently clean colonoscopies with no polyps and who is already 37 years old,is most likely not carrying the FAP gene. There is only a very small chance that she will start to develop polyps at this point, but since there is still a small chance, she should continue to have periodic colonoscopies. If she is basing her conclusion on the lack of symptoms only, and has not had colonoscopy screening, then we cannot make any judgments at this point.
Genetic testing for mutations in the APC gene that leads to FAP has improved over the last several years, and is a little more sensitive and able to find mutations now than in the past. A genetic counselor can look at the genetic testing report and determine if testing was done by sequencing, including testing for large deletions and rearrangements. If this type of sequencing testing was done, and no mutation was detected, then there is nothing else to do at this point testing-wise. The story of your family clearly represents FAP, and hopefully there will be technological enhancements in the future that allow for more informative testing in more families. If a family member with FAP has not yet had the testing mentioned above, it would be a good idea to have the testing done. Until then, everyone at 50% risk for FAP needs to start colonoscopy screening between 10 and 12 years.
What every person should know about screening, learning about your disease and the importance of cllinical research. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

